Free Trial

Alnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at HC Wainwright

Alnylam Pharmaceuticals logo with Medical background

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $400.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 54.88% from the company's current price.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald reissued a "neutral" rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Chardan Capital reiterated a "buy" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. Finally, Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Read Our Latest Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $20.29 during trading on Monday, reaching $258.27. 1,223,011 shares of the company's stock traded hands, compared to its average volume of 652,571. The company has a market capitalization of $33.31 billion, a P/E ratio of -98.58 and a beta of 0.34. The firm's 50-day moving average is $248.88 and its 200 day moving average is $259.75. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company's revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.15 EPS. Equities research analysts expect that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares of the company's stock, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,122 shares of company stock valued at $2,540,455. Company insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company's stock worth $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company's stock worth $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 33.3% in the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company's stock worth $97,200,000 after buying an additional 100,000 shares during the last quarter. Swiss National Bank grew its stake in Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company's stock worth $103,246,000 after buying an additional 1,000 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 25.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company's stock valued at $85,889,000 after purchasing an additional 63,385 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?

Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines